Research Paper Volume 13, Issue 2 pp 1929—1946

A TP53-based immune prognostic model for muscle-invasive bladder cancer

Prognosis of different TP53 mutations in TCGA MIBC cohort. (A) Kaplan-Meier survival analysis between the wild-type TP53 patients and mutated TP53 patients. (B) Kaplan-Meier survival analysis between the high and low risk subgroup in mutated TP53 MIBC patients. (C) Kaplan-Meier survival analysis between the high and low risk subgroup in wild-type TP53 MIBC patients. (D) Correlation analysis between risk score and survival time according to TP53 status. (E) Kaplan-Meier survival analysis among the different types of TP53mutations. (F) Kaplan-Meier survival analysis between the high and low risk subgroup in TP53 MIBC missense mutation patients.

Figure 3. Prognosis of different TP53 mutations in TCGA MIBC cohort. (A) Kaplan-Meier survival analysis between the wild-type TP53 patients and mutated TP53 patients. (B) Kaplan-Meier survival analysis between the high and low risk subgroup in mutated TP53 MIBC patients. (C) Kaplan-Meier survival analysis between the high and low risk subgroup in wild-type TP53 MIBC patients. (D) Correlation analysis between risk score and survival time according to TP53 status. (E) Kaplan-Meier survival analysis among the different types of TP53mutations. (F) Kaplan-Meier survival analysis between the high and low risk subgroup in TP53 MIBC missense mutation patients.